- Home
- MIN vs PRQR Comparison
MIN vs PRQR Comparison
Compare MIN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- PRQR
- Stock Information
- Founded
- MIN 1988
- PRQR 2012
- Country
- MIN United States
- PRQR Netherlands
- Employees
- MIN N/A
- PRQR N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- MIN Finance
- PRQR Health Care
- Exchange
- MIN Nasdaq
- PRQR Nasdaq
- Market Cap
- MIN 305.0M
- PRQR 309.5M
- IPO Year
- MIN N/A
- PRQR 2014
- Fundamental
- Price
- MIN $2.70
- PRQR $2.56
- Analyst Decision
- MIN
- PRQR Strong Buy
- Analyst Count
- MIN 0
- PRQR 6
- Target Price
- MIN N/A
- PRQR $8.17
- AVG Volume (30 Days)
- MIN 331.0K
- PRQR 286.6K
- Earning Date
- MIN 01-01-0001
- PRQR 03-12-2025
- Dividend Yield
- MIN 7.31%
- PRQR N/A
- EPS Growth
- MIN N/A
- PRQR N/A
- EPS
- MIN 0.08
- PRQR N/A
- Revenue
- MIN N/A
- PRQR $20,506,357.00
- Revenue This Year
- MIN N/A
- PRQR $210.18
- Revenue Next Year
- MIN N/A
- PRQR $33.25
- P/E Ratio
- MIN $33.38
- PRQR N/A
- Revenue Growth
- MIN N/A
- PRQR 306.68
- 52 Week Low
- MIN $2.52
- PRQR $1.61
- 52 Week High
- MIN $2.88
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- MIN 52.17
- PRQR 56.93
- Support Level
- MIN $2.66
- PRQR $2.47
- Resistance Level
- MIN $2.72
- PRQR $2.67
- Average True Range (ATR)
- MIN 0.03
- PRQR 0.18
- MACD
- MIN -0.00
- PRQR 0.07
- Stochastic Oscillator
- MIN 58.33
- PRQR 83.58
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.